ArticleFrontiers in physiology2026
Intraoperative tranexamic acid use in elderly patients with intertrochanteric fractures: impact on early postoperative inflammation and clinical outcomes.
Article in Frontiers in physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Tranexamic acid (TXA) demonstrates anti-inflammatory effects during surgery. However, the clinical value of the TXA in intertrochanteric fractures patients has not been further investigated. This study aimed to investigate the effects of intraoperative tranexamic acid (TXA) administration on early postoperative inflammatory markers and clinical outcomes in elderly patients with intertrochanteric fractures. Patients and methods: A total of 136 patients (59 males and 77 females) aged 62-96 years were enrolled. Patients were divided into two groups: 68 received TXA [TXA group, intravenous drip (15 mg/kg)] and 68 did not receive TXA (control group). We compared surgical duration, total blood loss (TBL), hidden blood loss (HBL), transfusion rates, incidence of deep vein thrombosis (DVT), length of hospital stay, serum interleukin-6 (IL-6) levels on postoperative days 1, 3, 5, and 7, and visual analog scale (VAS) scores. Results: The TXA group exhibited significantly lower TBL (981.74 ± 451.14 mL vs. 1206.27 ± 408.22 mL, p = 0.002), HBL (890.94 ± 409.99 mL vs. 1104.39 ± 412.06 mL, p = 0.003), and transfusion rates (32.3% vs. 51.4%, p = 0.037) compared with the control group. Serum IL-6 levels and VAS scores were significantly lower in the TXA group on postoperative days 1 and 3 (p < 0.05). The complication rate within one year was also lower in the TXA group (26.4% vs. 48.5%, p = 0.032). No significant differences were observed between groups for surgical duration, DVT incidence, length of hospital stay, or one-year mortality (p > 0.05). Conclusion: Intraoperative TXA administration appears to effectively reduce blood loss, attenuate the inflammatory response, and lower complication rates in elderly patients undergoing surgery for intertrochanteric fractures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.